Clinical utility of targeted next‐generation sequencing for the diagnosis of myeloid neoplasms with germline predisposition

Myeloid neoplasms (MN) with germline predisposition (MNGP) are likely to be more common than currently appreciated. Many of the genes involved in MNGP are also recurrently mutated in sporadic MN. Therefore, routine analysis of gene panels by next‐generation sequencing provides an effective approach...

Full description

Bibliographic Details
Main Authors: Cristina Andrés‐Zayas, Julia Suárez‐González, Gabriela Rodríguez‐Macías, Nieves Dorado, Santiago Osorio, Patricia Font, Diego Carbonell, María Chicano, Paula Muñiz, Mariana Bastos, Mi Kwon, José Luis Díez‐Martín, Ismael Buño, Carolina Martínez‐Laperche
Format: Article
Language:English
Published: Wiley 2021-09-01
Series:Molecular Oncology
Subjects:
Online Access:https://doi.org/10.1002/1878-0261.12921
id doaj-28d37e0d23014ce69edcf3d7dc5605f7
record_format Article
spelling doaj-28d37e0d23014ce69edcf3d7dc5605f72021-09-02T02:01:46ZengWileyMolecular Oncology1574-78911878-02612021-09-011592273228410.1002/1878-0261.12921Clinical utility of targeted next‐generation sequencing for the diagnosis of myeloid neoplasms with germline predispositionCristina Andrés‐Zayas0Julia Suárez‐González1Gabriela Rodríguez‐Macías2Nieves Dorado3Santiago Osorio4Patricia Font5Diego Carbonell6María Chicano7Paula Muñiz8Mariana Bastos9Mi Kwon10José Luis Díez‐Martín11Ismael Buño12Carolina Martínez‐Laperche13Genomics Unit Gregorio Marañón General University Hospital Gregorio Marañón Health Research Institute (IiSGM) Madrid SpainGenomics Unit Gregorio Marañón General University Hospital Gregorio Marañón Health Research Institute (IiSGM) Madrid SpainDepartment of Hematology Gregorio Marañón General University Hospital Madrid SpainGregorio Marañón Health Research Institute (IiSGM) Madrid SpainGregorio Marañón Health Research Institute (IiSGM) Madrid SpainGregorio Marañón Health Research Institute (IiSGM) Madrid SpainGregorio Marañón Health Research Institute (IiSGM) Madrid SpainGregorio Marañón Health Research Institute (IiSGM) Madrid SpainGregorio Marañón Health Research Institute (IiSGM) Madrid SpainGregorio Marañón Health Research Institute (IiSGM) Madrid SpainGregorio Marañón Health Research Institute (IiSGM) Madrid SpainGregorio Marañón Health Research Institute (IiSGM) Madrid SpainGenomics Unit Gregorio Marañón General University Hospital Gregorio Marañón Health Research Institute (IiSGM) Madrid SpainGregorio Marañón Health Research Institute (IiSGM) Madrid SpainMyeloid neoplasms (MN) with germline predisposition (MNGP) are likely to be more common than currently appreciated. Many of the genes involved in MNGP are also recurrently mutated in sporadic MN. Therefore, routine analysis of gene panels by next‐generation sequencing provides an effective approach to detect germline variants with clinical significance in patients with hematological malignancies. Gene panel sequencing was performed in 88 consecutive and five nonconsecutive patients with MN diagnosis. Disease‐causing germline mutations in CEBPα, ASXL1, TP53, MPL, GATA2, DDX41, and ETV6 genes were identified in nine patients. Six out of the nine patients with germline variants had a strong family history. These patients presented great heterogeneity in the age of diagnosis and phenotypic characteristics. In our study, there were families in which all the affected members presented the same subtype of disease, whereas members of other families presented various disease phenotypes. This intrafamiliar heterogeneity suggests that the acquisition of particular somatic variants may drive the evolution of the disease. This approach enabled high‐throughput detection of MNGP in patients with MN diagnosis, which is of great relevance for both the patients themselves and the asymptomatic mutation carriers within the family. It is crucial to make a proper diagnosis of these patients to provide them with the most suitable treatment, follow‐up, and genetic counseling.https://doi.org/10.1002/1878-0261.12921family historygenetic counselinghereditary cancermyeloid neoplasms with germline predispositionnext‐generation sequencing
collection DOAJ
language English
format Article
sources DOAJ
author Cristina Andrés‐Zayas
Julia Suárez‐González
Gabriela Rodríguez‐Macías
Nieves Dorado
Santiago Osorio
Patricia Font
Diego Carbonell
María Chicano
Paula Muñiz
Mariana Bastos
Mi Kwon
José Luis Díez‐Martín
Ismael Buño
Carolina Martínez‐Laperche
spellingShingle Cristina Andrés‐Zayas
Julia Suárez‐González
Gabriela Rodríguez‐Macías
Nieves Dorado
Santiago Osorio
Patricia Font
Diego Carbonell
María Chicano
Paula Muñiz
Mariana Bastos
Mi Kwon
José Luis Díez‐Martín
Ismael Buño
Carolina Martínez‐Laperche
Clinical utility of targeted next‐generation sequencing for the diagnosis of myeloid neoplasms with germline predisposition
Molecular Oncology
family history
genetic counseling
hereditary cancer
myeloid neoplasms with germline predisposition
next‐generation sequencing
author_facet Cristina Andrés‐Zayas
Julia Suárez‐González
Gabriela Rodríguez‐Macías
Nieves Dorado
Santiago Osorio
Patricia Font
Diego Carbonell
María Chicano
Paula Muñiz
Mariana Bastos
Mi Kwon
José Luis Díez‐Martín
Ismael Buño
Carolina Martínez‐Laperche
author_sort Cristina Andrés‐Zayas
title Clinical utility of targeted next‐generation sequencing for the diagnosis of myeloid neoplasms with germline predisposition
title_short Clinical utility of targeted next‐generation sequencing for the diagnosis of myeloid neoplasms with germline predisposition
title_full Clinical utility of targeted next‐generation sequencing for the diagnosis of myeloid neoplasms with germline predisposition
title_fullStr Clinical utility of targeted next‐generation sequencing for the diagnosis of myeloid neoplasms with germline predisposition
title_full_unstemmed Clinical utility of targeted next‐generation sequencing for the diagnosis of myeloid neoplasms with germline predisposition
title_sort clinical utility of targeted next‐generation sequencing for the diagnosis of myeloid neoplasms with germline predisposition
publisher Wiley
series Molecular Oncology
issn 1574-7891
1878-0261
publishDate 2021-09-01
description Myeloid neoplasms (MN) with germline predisposition (MNGP) are likely to be more common than currently appreciated. Many of the genes involved in MNGP are also recurrently mutated in sporadic MN. Therefore, routine analysis of gene panels by next‐generation sequencing provides an effective approach to detect germline variants with clinical significance in patients with hematological malignancies. Gene panel sequencing was performed in 88 consecutive and five nonconsecutive patients with MN diagnosis. Disease‐causing germline mutations in CEBPα, ASXL1, TP53, MPL, GATA2, DDX41, and ETV6 genes were identified in nine patients. Six out of the nine patients with germline variants had a strong family history. These patients presented great heterogeneity in the age of diagnosis and phenotypic characteristics. In our study, there were families in which all the affected members presented the same subtype of disease, whereas members of other families presented various disease phenotypes. This intrafamiliar heterogeneity suggests that the acquisition of particular somatic variants may drive the evolution of the disease. This approach enabled high‐throughput detection of MNGP in patients with MN diagnosis, which is of great relevance for both the patients themselves and the asymptomatic mutation carriers within the family. It is crucial to make a proper diagnosis of these patients to provide them with the most suitable treatment, follow‐up, and genetic counseling.
topic family history
genetic counseling
hereditary cancer
myeloid neoplasms with germline predisposition
next‐generation sequencing
url https://doi.org/10.1002/1878-0261.12921
work_keys_str_mv AT cristinaandreszayas clinicalutilityoftargetednextgenerationsequencingforthediagnosisofmyeloidneoplasmswithgermlinepredisposition
AT juliasuarezgonzalez clinicalutilityoftargetednextgenerationsequencingforthediagnosisofmyeloidneoplasmswithgermlinepredisposition
AT gabrielarodriguezmacias clinicalutilityoftargetednextgenerationsequencingforthediagnosisofmyeloidneoplasmswithgermlinepredisposition
AT nievesdorado clinicalutilityoftargetednextgenerationsequencingforthediagnosisofmyeloidneoplasmswithgermlinepredisposition
AT santiagoosorio clinicalutilityoftargetednextgenerationsequencingforthediagnosisofmyeloidneoplasmswithgermlinepredisposition
AT patriciafont clinicalutilityoftargetednextgenerationsequencingforthediagnosisofmyeloidneoplasmswithgermlinepredisposition
AT diegocarbonell clinicalutilityoftargetednextgenerationsequencingforthediagnosisofmyeloidneoplasmswithgermlinepredisposition
AT mariachicano clinicalutilityoftargetednextgenerationsequencingforthediagnosisofmyeloidneoplasmswithgermlinepredisposition
AT paulamuniz clinicalutilityoftargetednextgenerationsequencingforthediagnosisofmyeloidneoplasmswithgermlinepredisposition
AT marianabastos clinicalutilityoftargetednextgenerationsequencingforthediagnosisofmyeloidneoplasmswithgermlinepredisposition
AT mikwon clinicalutilityoftargetednextgenerationsequencingforthediagnosisofmyeloidneoplasmswithgermlinepredisposition
AT joseluisdiezmartin clinicalutilityoftargetednextgenerationsequencingforthediagnosisofmyeloidneoplasmswithgermlinepredisposition
AT ismaelbuno clinicalutilityoftargetednextgenerationsequencingforthediagnosisofmyeloidneoplasmswithgermlinepredisposition
AT carolinamartinezlaperche clinicalutilityoftargetednextgenerationsequencingforthediagnosisofmyeloidneoplasmswithgermlinepredisposition
_version_ 1721181571853058048